John R. Stuelpnagel sold 20,000 10x Genomics shares at prices ranging from $60.66 to $62.61 across three transactions, leaving him with 328,436 shares. Investors can see the sale’s execution range and the insider’s resulting ownership position from the reported transaction details.
Key Highlights
- The transactions occurred on 3 September 2026.
- Stuelpnagel owned 328,436 shares after the transactions.
- All three transactions carried code S.
10x Genomics, Inc. (NASDAQ: TXG) insider John R. Stuelpnagel sold 20,000 shares. The three transactions took place at prices ranging from $60.66 to $62.61 per share.
Three Transactions on 3 September 2026
The transactions were completed on 3 September 2026, with each carrying transaction code S. The activity was divided across three transactions, and the prices covered the range from $60.66 to $62.61 per share. Stuelpnagel held 328,436 shares after the transactions. 10x Genomics identifies Stuelpnagel as an insider. The reported sale involved 20,000 shares in total, while the post-transaction ownership figure was 328,436 shares.
FAQs
Q: How many 10x Genomics shares did John R. Stuelpnagel sell?
A: John R. Stuelpnagel sold 20,000 10x Genomics shares. The filing states that the sale occurred through three transactions on 3 September 2026.
Q: What prices were paid in the 10x Genomics insider sale?
A: The 10x Genomics shares changed hands at prices ranging from $60.66 to $62.61 per share across the three reported transactions.
Q: How many shares did the 10x Genomics insider retain?
A: John R. Stuelpnagel owned 328,436 10x Genomics shares after the transactions. The filing reports that all three transactions carried transaction code S.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.